Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma

Current Medical Research and Opinion

Volumn 25, Issue 5, 2009, Pages 1105-1109

  Barker, L C ^a   Brand, I R ^a   Crawford, S M ^a  

^a AIREDALE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitors; Endometrial carcinoma; Endometrial hyperplasia; Obesity; Ultrasound

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG EFFECT; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; METASTASIS; POSTMENOPAUSE; RETROSPECTIVE STUDY; TRANSVAGINAL ECHOGRAPHY; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; CARCINOMA; DISEASE PROGRESSION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NITRILES; ORGAN SIZE; RETROSPECTIVE STUDIES; TIME FACTORS; TRIAZOLES;

EID: 67649403232     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902860549     Document Type: Article

References (9)

1. Grimbizis G, Tsalikis T, Tzioufa V, et al. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: A prospective study. Hum Reprod 1999;14:479-484 (Pubitemid 29097406)
2. Baanders-van Halewyn EA, Blankenstein MA, Thijssen JH, et al. A comparative study of risk factors for hyperplasia and cancer of the endometrium. Eur J Cancer Prev 1996;5:105-112 (Pubitemid 26183609)
3. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), as a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74:1286-1291 (Pubitemid 26360121)
4. Bajetta E, Zilembo N, Dowsett M, et al. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 1999;35:208-213 (Pubitemid 29136769)
5. Agorastos T, Vaitsi V, Pantazis K, et al. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005;118:239-240 (Pubitemid 40093842)
6. Nasri MN, Shepherd JH, Setchell ME, et al. The role of vaginal scan in measurement of endometrial thickness in postmenopausal women. Br J Obstet Gynaecol 1991;98:470-475
7. Varma R, Soneja H, Bhatia K, et al. The effectiveness of a levonorgestrel-releasing intrauterine system(LNG-IUS) in the treatment of endometrial hyperplasia - a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139: 169-175
8. Ørbo A, Arnes M, Hancke C, et al. Treatment results of endometrial hyperplasia after prospective D-score classification. A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111: 68-73
9. Garuti G, Cellani F, Centinaio G, et al. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors. Gynecol Oncol, 2006; 103:599-603 (Pubitemid 44602174)